Generic Loestrin 21 1.5/30 Availability
LOESTRIN 21 1.5/30 (ethinyl estradiol; norethindrone acetate - tablet;oral-21)
Has a generic version of Loestrin 21 1.5/30 been approved?
Yes. The following products are equivalent to Loestrin 21 1.5/30:
Approval date: May 30, 2003
Strength(s): 0.03MG;1.5MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Loestrin 21 1.5/30. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Loestrin 21 1.5/30.
- Loestrin 21 1.5/30 birth control Consumer Information (Cerner Multum)
- Loestrin Fe Consumer Information (Wolters Kluwer)
- Microgestin Fe Consumer Information (Wolters Kluwer)
- Norethindrone/ethinyl estradiol Consumer Information (Wolters Kluwer)
- Norethindrone/ethinyl estradiol (HRT) Consumer Information (Wolters Kluwer)
- Norethindrone/ethinyl estradiol chewable tablets Consumer Information (Wolters Kluwer)
- Norethindrone/ethinyl estradiol tablets Consumer Information (Wolters Kluwer)
- Gildess birth control Consumer Information (Cerner Multum)
- Ethinyl estradiol and norethindrone HRT Consumer Information (Cerner Multum)
- Ethinyl estradiol and norethindrone birth control Consumer Information (Cerner Multum)
- Femhrt Lo Advanced Consumer Information (Micromedex)
- Loestrin 1.5/30 Oral Advanced Consumer Information (Micromedex)
- Ethinyl estradiol and norethindrone Advanced Consumer Information (Micromedex)
- Norethindrone, ethinyl estradiol, and ferrous fumarate Advanced Consumer Information (Micromedex)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|AB||Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.|